vs
Kimball Electronics, Inc.（KE）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Kimball Electronics, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.6倍（$341.3M vs $207.3M），Kimball Electronics, Inc.净利率更高（1.1% vs -62.0%，领先63.1%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -4.5%），Kimball Electronics, Inc.自由现金流更多（$-11.2M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -10.4%）
金伯尔国际是一家美国企业，旗下拥有金伯尔、国民、Interwoven等多个家具品牌，业务涵盖酒店家具等多元产品线。它的前身是19至20世纪一度成为全球最大钢琴与管风琴制造商的W.W.金伯尔公司，如今转型聚焦商用家具领域发展。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
KE vs RARE — 直观对比
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $341.3M | $207.3M |
| 净利润 | $3.6M | $-128.6M |
| 毛利率 | 8.2% | — |
| 营业利润率 | 3.2% | -54.7% |
| 净利率 | 1.1% | -62.0% |
| 营收同比 | -4.5% | 25.9% |
| 净利润同比 | 6.0% | 3.5% |
| 每股收益（稀释后） | $0.15 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $341.3M | $207.3M | ||
| Q3 25 | $365.6M | $159.9M | ||
| Q2 25 | $380.5M | $166.5M | ||
| Q1 25 | $374.6M | $139.3M | ||
| Q4 24 | $357.4M | $164.6M | ||
| Q3 24 | $374.3M | $139.5M | ||
| Q2 24 | $430.2M | $147.0M | ||
| Q1 24 | $425.0M | $108.8M |
| Q4 25 | $3.6M | $-128.6M | ||
| Q3 25 | $10.1M | $-180.4M | ||
| Q2 25 | $6.6M | $-115.0M | ||
| Q1 25 | $3.8M | $-151.1M | ||
| Q4 24 | $3.4M | $-133.2M | ||
| Q3 24 | $3.2M | $-133.5M | ||
| Q2 24 | $7.5M | $-131.6M | ||
| Q1 24 | $-6.1M | $-170.7M |
| Q4 25 | 8.2% | — | ||
| Q3 25 | 7.9% | — | ||
| Q2 25 | 8.0% | — | ||
| Q1 25 | 7.2% | — | ||
| Q4 24 | 6.6% | — | ||
| Q3 24 | 6.3% | — | ||
| Q2 24 | 8.5% | — | ||
| Q1 24 | 7.9% | — |
| Q4 25 | 3.2% | -54.7% | ||
| Q3 25 | 4.0% | -106.9% | ||
| Q2 25 | 4.3% | -64.8% | ||
| Q1 25 | 3.1% | -102.6% | ||
| Q4 24 | 2.3% | -74.3% | ||
| Q3 24 | 2.4% | -94.6% | ||
| Q2 24 | 4.6% | -79.1% | ||
| Q1 24 | -1.5% | -151.9% |
| Q4 25 | 1.1% | -62.0% | ||
| Q3 25 | 2.8% | -112.8% | ||
| Q2 25 | 1.7% | -69.0% | ||
| Q1 25 | 1.0% | -108.5% | ||
| Q4 24 | 1.0% | -80.9% | ||
| Q3 24 | 0.8% | -95.7% | ||
| Q2 24 | 1.8% | -89.5% | ||
| Q1 24 | -1.4% | -156.8% |
| Q4 25 | $0.15 | $-1.28 | ||
| Q3 25 | $0.40 | $-1.81 | ||
| Q2 25 | $0.27 | $-1.17 | ||
| Q1 25 | $0.15 | $-1.57 | ||
| Q4 24 | $0.14 | $-1.34 | ||
| Q3 24 | $0.12 | $-1.40 | ||
| Q2 24 | $0.29 | $-1.52 | ||
| Q1 24 | $-0.24 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $421.0M |
| 总债务越低越好 | $153.8M | — |
| 股东权益账面价值 | $579.2M | $-80.0M |
| 总资产 | $1.1B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.27× | — |
8季度趋势，按日历期对齐
| Q4 25 | $77.9M | $421.0M | ||
| Q3 25 | $75.7M | $202.5M | ||
| Q2 25 | $88.8M | $176.3M | ||
| Q1 25 | $51.4M | $127.1M | ||
| Q4 24 | $53.9M | $174.0M | ||
| Q3 24 | $76.6M | $150.6M | ||
| Q2 24 | $78.0M | $480.7M | ||
| Q1 24 | $65.2M | $112.3M |
| Q4 25 | $153.8M | — | ||
| Q3 25 | $137.5M | — | ||
| Q2 25 | $147.1M | — | ||
| Q1 25 | $178.3M | — | ||
| Q4 24 | $204.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $294.8M | — | ||
| Q1 24 | — | — |
| Q4 25 | $579.2M | $-80.0M | ||
| Q3 25 | $577.1M | $9.2M | ||
| Q2 25 | $569.9M | $151.3M | ||
| Q1 25 | $548.1M | $144.2M | ||
| Q4 24 | $537.5M | $255.0M | ||
| Q3 24 | $547.8M | $346.8M | ||
| Q2 24 | $540.5M | $432.4M | ||
| Q1 24 | $539.1M | $140.3M |
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.1B | $1.3B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.1B | $1.5B | ||
| Q3 24 | $1.1B | $1.5B | ||
| Q2 24 | $1.2B | $1.6B | ||
| Q1 24 | $1.3B | $1.3B |
| Q4 25 | 0.27× | — | ||
| Q3 25 | 0.24× | — | ||
| Q2 25 | 0.26× | — | ||
| Q1 25 | 0.33× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.55× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $6.9M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-11.2M | $-100.8M |
| 自由现金流率自由现金流/营收 | -3.3% | -48.6% |
| 资本支出强度资本支出/营收 | 5.3% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.89× | — |
| 过去12个月自由现金流最近4个季度 | $81.8M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $6.9M | $-99.8M | ||
| Q3 25 | $8.1M | $-91.4M | ||
| Q2 25 | $78.1M | $-108.3M | ||
| Q1 25 | $30.9M | $-166.5M | ||
| Q4 24 | $29.5M | $-79.3M | ||
| Q3 24 | $45.5M | $-67.0M | ||
| Q2 24 | $48.5M | $-77.0M | ||
| Q1 24 | $42.6M | $-190.7M |
| Q4 25 | $-11.2M | $-100.8M | ||
| Q3 25 | $-2.5M | $-92.7M | ||
| Q2 25 | $68.4M | $-110.7M | ||
| Q1 25 | $27.0M | $-167.8M | ||
| Q4 24 | $23.1M | $-79.5M | ||
| Q3 24 | $32.1M | $-68.6M | ||
| Q2 24 | $39.5M | $-79.0M | ||
| Q1 24 | $30.0M | $-193.9M |
| Q4 25 | -3.3% | -48.6% | ||
| Q3 25 | -0.7% | -58.0% | ||
| Q2 25 | 18.0% | -66.5% | ||
| Q1 25 | 7.2% | -120.5% | ||
| Q4 24 | 6.5% | -48.3% | ||
| Q3 24 | 8.6% | -49.2% | ||
| Q2 24 | 9.2% | -53.7% | ||
| Q1 24 | 7.1% | -178.2% |
| Q4 25 | 5.3% | 0.5% | ||
| Q3 25 | 2.9% | 0.8% | ||
| Q2 25 | 2.5% | 1.5% | ||
| Q1 25 | 1.0% | 1.0% | ||
| Q4 24 | 1.8% | 0.1% | ||
| Q3 24 | 3.6% | 1.2% | ||
| Q2 24 | 2.1% | 1.4% | ||
| Q1 24 | 3.0% | 3.0% |
| Q4 25 | 1.89× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 11.86× | — | ||
| Q1 25 | 8.11× | — | ||
| Q4 24 | 8.58× | — | ||
| Q3 24 | 14.42× | — | ||
| Q2 24 | 6.43× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KE
| Automotive | $162.3M | 48% |
| Medical | $96.3M | 28% |
| Industrial | $82.7M | 24% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
